

**DIVA: Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein graft Angioplasty**

Principal Investigator : Anand Irimpen, MD  
Sponsor: VA Office of Research and Development  
ClinicalTrials.gov - NCT01121224

**RELAX-AHF-2: A multicenter, randomized, double-blind, placebo- controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients**

Principal Investigator: Thierry Le Jemtel, MD  
Sponsor: Novartis Pharmaceuticals  
ClinicalTrials.gov - NCT01870778

**REDUAL - PCI: A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAf) that have undergone a percutaneous coronary intervention (PCI) with stenting**

Principal Investigator: Anand Irimpen, MD  
Sponsor: Boehringer-Ingelheim  
ClinicalTrials.gov - NCT02164864

**RE-CIRCUIT: Randomised Evaluation of dabigatran etexilate Compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation**

Principal Investigator : Colleen Johnson, MD  
Sponsor: Boehringer-Ingelheim  
ClinicalTrials.gov - NCT02348723

**ORBIT-AF II - Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II**

Principal Investigator : Anand Irimpen, MD  
Sponsor: Janssen-Scientific  
ClinicalTrials.gov - NCT01701817

**GARFIELD-AF: Prospective, multi center, international registry of male and female patients newly diagnosed with atrial fibrillation**

Principal Investigator : Keith Ferdinand, MD  
Sponsor: London Thrombosis Institute  
ClinicalTrials.gov - NCT01090362

**GARFIELD-VTE: Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world**

Principal Investigator : Gholam Ali, MD

Sponsor: London Thrombosis Institute

ClinicalTrials.gov - NCT02155491

**USpella: Impella 2.5, Impella 5.0, Impella LD and Impella CP Data Registry**

Principal Investigator : Nidal Abi Rafeh, MD

Sponsor: Abiomed, INC

**ODYSSEY-OUTCOMES: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary**

Principal Investigator: Alvaro Alonso MD

Sponsor: Sanofi

ClinicalTrials.gov - NCT01663402

**CANTOS-A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated**

Principal Investigator : Keith Ferdinand, MD

Sponsor: Novartis

ClinicalTrials.gov - NCT01327846